康希諾生物-B(06185.HK)預計年度淨虧損4億元-4.3億元
格隆匯 1 月 28日丨康希諾生物-B(06185.HK)公佈,預計截至2020年12月31日止年度實現歸屬於母公司所有者的淨虧損為人民幣4億元到人民幣4.3億元,與截至2019年12月31日止年度約人民幣1.568億元相比,增加155.1%到174.3%。
預計截至2020年12月31日止年度實現歸屬於母公司所有者的扣除非經常性損益的淨虧損為人民幣5.10億元到人民幣5.4億元,與截至2019年12月31日止年度約人民幣1.744億元相比,增加192.4%到209.6%。
該期業績變化的主要原因:
影響報吿期內,公司加大研發投入,尤其是新冠疫情爆發以來,推進重組新型冠狀病毒疫苗(腺病毒載體)的研發進展,研發費用大幅上升;此外,公司積極推進產品商業化進展,員工數量及各項運營支出持續增加。因此,歸屬於母公司所有者的淨虧損進一步增加;及主要為該期政府補助及閒置募集資金現金管理收益增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.